Integrated Filing — IndAS



General information about company

Scrip Code 544067
NSE Symbol INNOVACAP
MSEI Symbol NOTLISTED
ISIN INE0DUT01020
Name of company INNOVA CAPTAB LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 13-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 05-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Drugs and Pharmaceutical products
Start date and time of board meeting 13-11-2026   15:04:00
End date and time of board meeting 13-11-2026   15:42:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 07-05-2026
Indicate Company website link for updated RPT policy of the Company https://www.innovacaptab.com/Policy_on_RPT.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? Yes



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 40,477.50 80,525.10
Other income 290.00 560.20
Total income 40,767.50 81,085.30
2 Expenses
(a) Cost of materials consumed 29,684.30 57,720.90
(b) Purchases of stock-in-trade 44.00 694.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (491.30) (566.60)
(d) Employee benefit expense 2,952.40 5,986.90
(e) Finance costs 395.30 798.60
(f) Depreciation, depletion and amortisation expense 989.30 1,957.70
(f) Other Expenses
1 Power and fuel 778.00 1,390.40
2 Packing charges 498.90 956.40
3 Stores and spares consumed 252.20 544.60
4 Commission on sales 84.10 159.30
5 Freight charges 575.40 1,149.90
6 House keeping expense 121.30 235.70
7 Travelling and conveyance 102.20 191.20
8 Lab consumables 135.10 243.10
9 Rates, fees and taxes 179.40 325.40
10 Miscellaneous expenses 264.70 792.20
Total other expenses 2,991.30 5,988.20
Total expenses 36,565.30 72,579.70
3 Total profit before exceptional items and tax 4,202.20 8,505.60
4 Exceptional items 0.00 0.00
5 Total profit before tax 4,202.20 8,505.60
6 Tax expense
7 Current tax 973.20 1,664.50
8 Deferred tax 32.10 438.20
9 Total tax expenses 1,005.30 2,102.70
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,196.90 6,402.90
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 3,196.90 6,402.90
17 Other comprehensive income net of taxes (40.90) (53.50)
18 Total Comprehensive Income for the period 3,156.00 6,349.40
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 5,722.50 5,722.50
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 5.59 11.19
Diluted earnings (loss) per share from continuing operations 5.59 11.19
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.59 11.19
Diluted earnings (loss) per share from continuing and discontinued operations 5.59 11.19
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) The above unaudited standalone financial results of Innova Captab Limited the Company have been prepared in accordance with recognition and measurement principles laid down under Indian Accounting Standard 34 Interim Financial Reporting Ind AS 34 prescribed under Section 133 of the Companies Act 2013 the act read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 Listing Regulation as amended The results for the quarter and half year ended 30 September 2026 are available on the Companys website www innovacaptab com under investor relations section and on the stock exchange websites www nseindia com and www bseindia com The above unaudited standalone financial results have been reviewed and recommended by Audit Committee at its meeting held on 13 November 2026 The Board of Directors at their meeting held on 13 November 2026 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the unaudited standalone financial results for the quarter and half year ended 30 September 2026 The Company has only one reportable segment Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per SEBI LODR regulations or Listing Regulations are not applicable to the Company



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 64,730.50
Capital work-in-progress 581.30
Investment property 0.00
Goodwill 0.00
Other intangible assets 137.90
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 6,000.00
Trade receivables, non-current 0.00
Loans, non-current 47.90
Other non-current financial assets
1 Security deposit 99.50
2 Balance with banks-deposits with more than 12 months maturity 703.40
Total of other non-current financial assets 802.90
Total non-current financial assets 6,850.80
Deferred tax assets (net) 0.00
Other non-current assets
1 Capital advances 2,130.40
2 Prepaid expenses 102.00
Total of other non-current assets 2,232.40
Total non-current assets 74,532.90
2 Current assets
Inventories 22,148.10
Current financial asset
Current investments 8,293.70
Trade receivables, current 39,449.00
Cash and cash equivalents 1,468.90
Bank balance other than cash and cash equivalents 0.20
Loans, current 1,145.90
Other current financial assets
Total of other current financial assets 13,347.80
Total current financial assets 63,705.50
Current tax assets (net) 0.00
Other current assets
1 Advances to suppliers 129.60
2 Balances with government authorities 4,893.30
3 Advances to employees 3.60
4 Prepaid expenses 324.50
Total of other current assets 5,351.00
Total current assets 91,204.60
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,65,737.50
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 5,722.50
Other equity 89,416.20
Total equity attributable to owners of parent 95,138.70
Non controlling interest
Total equity 95,138.70
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 20,137.70
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
Total of other non-current financial liabilities
Total non-current financial liabilities 20,137.70
Provisions, non-current 761.50
Deferred tax liabilities (net) 2,649.60
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 23,548.80
Current liabilities
Current financial liabilities
Borrowings, current 12,828.60
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 5,017.10
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 24,690.40
Total Trade payable 29,707.50
Other current financial liabilities
1 Interest accrued but not due on borrowings 112.40
2 Employee related payables 1,282.70
3 Capital creditors 233.30
4 Supplier finance arrangements 2,126.40
5 Unclaimed dividend 0.20
Total of other current financial liabilities 3,755.00
Total current financial liabilities 46,291.10
Other current liabilities 283.70
1 Contract liabilities 119.10
2 Statutory dues 164.60
Total of other current liabilities 283.70
Provisions, current 220.30
Current tax liabilities (Net) 254.90
Deferred government grants, Current 0.00
Total current liabilities 47,050.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 70,598.80
Total equity and liabilites 1,65,737.50
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Amount of property plant and equipment also includes amount of right of use of assets Amount of borrowings also include amount of lease liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) The Company has only one reportable segment Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per SEBI LODR regulations or Listing Regulations are not applicable to the Company



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligation (54.60) (71.50)
2 Income tax relating to items that will not be reclassified to profit or loss 13.70 18.00
Total Amount of items that will not be reclassified to profit and loss (40.90) (53.50)
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income (40.90) (53.50)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 8,505.60
Adjustments for reconcile profit (loss)
Adjustments for finance costs 786.10
Adjustments for decrease (increase) in inventories (1,751.50)
Adjustments for decrease (increase) in trade receivables, current (6,584.10)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 185.30
Adjustments for decrease (increase) in other non-current assets 37.70
Adjustments for other financial assets, non-current (1,355.40)
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 2,898.90
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (90.70)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,957.70
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 119.10
Adjustments for provisions, current 46.10
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 509.60
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (90.40)
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (164.40)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (20.70)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 25.60
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (3,491.10)
Net cash flows from (used in) operations 5,014.50
Dividends received 0.00
Interest paid 0.00
Interest received (325.30)
Income taxes paid (refund) 1,482.40
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 3,206.80
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 46.30
Purchase of property, plant and equipment 2,017.70
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 28.30
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 4,000.80
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 3,875.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 155.30
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 56.70
Net cash flows from (used in) investing activities (1,913.50)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 2,214.80
Repayments of borrowings 1,383.60
Payments of lease liabilities 2.70
Dividends paid 0.00
Interest paid 796.40
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 32.10
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1,325.40
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 1,325.40
Cash and cash equivalents cash flow statement at beginning of period 143.50
Cash and cash equivalents cash flow statement at end of period 1,468.90





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Innova Captab Limited Nugenic Pharma Private Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala, Director, Promoter & Shareholder of the Innova Captab Limited are Director and shareholder in Nugenic Pharma Private Limited. Purchase of goods or services 10,500.00 Approved by Audit Committee 5,312.10 1,324.80 1,539.80
2 Innova Captab Limited Nugenic Pharma Private Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala, Director, Promoter & Shareholder of the Innova Captab Limited are Director and shareholder in Nugenic Pharma Private Limited. Sale of goods or services 100.00 Approved by Audit Committee 12.10 0.00 14.20
3 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala, Director, Promoter & Shareholder of the Innova Captab Limited are Director and nominee shareholder of Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company of the Innova Captab Limited Sale of goods or services NA 9,190.40 4,016.80 4,961.90
4 Innova Captab Limited Azine Healthcare Private Limited Mr. Shyamsundar Aggarwal (Brother of Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala) is a director in Azine Healthcare Private Limited Sale of goods or services 100.00 Approved by Audit Committee 2.20 50.10 52.40
5 Innova Captab Limited Pharmatech Healthcare Mr. Shyamsundar Aggarwal (Brother of Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala) is a Partner in Pharmatech Healthcare Sale of goods or services 250.00 Approved by Audit Committee 17.40 261.40 269.70
6 Innova Captab Limited Sharon Bio-Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio-Medicine Limited (SBML) and SBML is step down subsidiary of the Company Sale of goods or services NA 21.10 0.00 0.00
7 Innova Captab Limited Shubh Packaging Ms. Vandana Gohlyan (Sister of Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala,) is a partner in Shubh Packaging Purchase of goods or services 1,500.00 Approved by Audit Committee 651.70 147.10 184.00
8 Innova Captab Limited Sharon Bio-Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio-Medicine Limited (SBML) and SBML is step down subsidiary of the Company Purchase of goods or services NA 33.00 0.00 29.20
9 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala, Director, Promoter & Shareholder of the Company are Director and nominee shareholder of Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Purchase of goods or services NA 5.90 0.00 0.10
10 Innova Captab Limited Mukesh Kumar Singh Key Managerial Personnel Any other transaction Loan Repaid NA 1.50 5.00 3.50
11 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala, Directors, Promoter & Shareholder of the Company are Director and nominee shareholder of Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Interest received Loan approved by Board of Director 117.00 28.90 0.00
12 Innova Captab Limited Manoj Kumar Lohariwala Whole Time Director Remuneration Approved by Board of Directors 94.00 8.20 10.40
13 Innova Captab Limited Vinay Lohariwala Managing Director Remuneration Approved by Board of Directors 94.00 8.20 10.40
14 Innova Captab Limited Anshika Lohariwala Daughter of Chairman Remuneration Approved by Audit Committee & Board of Directors 16.30 2.00 2.30
15 Innova Captab Limited Sharon Bio-Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio Medicine Limited (SBML) and SBML is step down subsidiary of the Company Any other transaction Rent paid NA 7.80 0.00 0.00
16 Innova Captab Limited Univentis Medicare Limited Mr. Manoj Kumar Lohariwala and Mr. Vinay Lohariwala, Director, Promoter & Shareholder of the Company are Director and nominee shareholder Univentis Medicare Limited & Univentis Medicare Limited is Wholly Owned Subsidiary Company Any other transaction Rent received NA 14.30 2.50 0.00
17 Innova Captab Limited Sharon Bio-Medicine Limited Mr. Jayant Vasudeo Rao and Mr. Mahendar Korthiwada Directors of the Company are Directors in Sharon Bio Medicine Limited (SBML) and SBML is step down subsidiary of the Company Sale of fixed assets NA 6.00 0.00 0.00
Total value of transaction during the reporting period 15,596.80





Format for Disclosing Outstanding Default on Loans and Debt Securities

Amount in (Lakhs)

<
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date 0.00
B Of the total amount outstanding, amount of default as on date 0.00
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date 0.00
B Of the total amount outstanding, amount of default as on date 0.00
3. Total financial indebtedness of the listed entity including short-term and long-term debt 0.00